Rocket Pharmaceuticals (RCKT)
(Real Time Quote from BATS)
$3.01 USD
-0.06 (-1.95%)
Updated Aug 5, 2025 03:42 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RCKT 3.01 -0.06(-1.95%)
Will RCKT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RCKT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCKT
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
RCKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
RCKT Stock Tanks on Patient Death in Danon Disease Study
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
Other News for RCKT
Biotech stocks rise following Prasad exit from FDA
Biotech stocks rise following Prasad exit from FDA
Rocket Pharmaceuticals (RCKT) Target Price Revised, Strategic Focus Shifted | RCKT Stock News
Rocket Pharmaceuticals (RCKT) Downgraded by B of A Securities | RCKT Stock News
Rocket Pharmaceuticals price target lowered by $1 at Canaccord, here's why